Dexibuprofen Biodegradable Nanoparticles: One Step Closer towards a Better Ocular Interaction Study.

Area of Science:

• Ophthalmology
• Nanotechnology
• Pharmaceutics

Background:

• Ocular inflammation is a common condition requiring treatment.
• Topical non-steroidal anti-inflammatory drugs (NSAIDs) have poor ocular bioavailability (<5%).
• Drug delivery systems are needed to improve ocular drug penetration and reduce side effects.

Purpose of the Study:

• To develop and evaluate poly(lactic-co-glycolic)-acid (PLGA) nanoparticles for enhanced ocular delivery of dexibuprofen.
• To assess the potential of these nanoparticles to improve bioavailability and reduce side effects of ocular anti-inflammatory treatment.
• To investigate the in vitro and in vivo performance of dexibuprofen-loaded PLGA nanoparticles.

Main Methods:

• Preparation of PLGA nanoparticles encapsulating dexibuprofen using the solvent displacement method with various surfactants.
• Characterization of nanoparticle formulations.
• In vitro evaluation using a lipid corneal membrane model for permeation studies.
• Ex vivo permeation studies through ocular tissues.
• In vivo assessment of anti-inflammatory efficacy.

Main Results:

• PLGA nanoparticles demonstrated potential for improved ocular drug delivery.
• Formulations were characterized, and interactions with a corneal model were studied.
• Ex vivo and in vivo studies indicated promising anti-inflammatory effects and bioavailability enhancement.

Conclusions:

• Biodegradable PLGA nanoparticles offer a viable strategy for enhancing ocular dexibuprofen delivery.
• This approach can improve therapeutic outcomes for ocular inflammation by increasing bioavailability and reducing side effects.
• Nanoparticle-based drug delivery systems show promise for improving patient treatment adherence in ophthalmology.